Multiple myeloma · 8 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
KD-PACE Variant #01 | — | R 98 077 | 42d | — | — | ~3 | ~R 154 335 indirect | — |
KRD-PACE Variant #01 | — | R 40 832 | — | — | — | ~1 | ~R 40 832 indirect | — |
VMPT Variant #01 | — | R 12 072 | 42d | — | — | ~6 | ~R 72 429 PFS proxy · indirect | 2 |
Bortezomib, Thalidomide, Dexamethasone, Panobinostat Variant #01 Partial | — | R 9 984 | 21d | — | — | ~16 | ~R 159 745 indirect | — |
V-HyperCAD Variant #01 | — | R 4 780 | — | — | — | ~2 | ~R 9 561 indirect | — |
DTPACE Variant #01 | — | R 3 800 | 42d | — | — | ~2 | ~R 7 599 indirect | — |
Hyper-CVAD Variant #01 | — | R 2 286 | — | — | — | ~2 | ~R 4 571 indirect | — |
DCEP Variant #03 | — | R 2 157 | 28d | — | — | ~1 | ~R 2 157 indirect | — |
8 of 8 regimens shown